Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology

This page shows the latest Novartis Oncology news and features for those working in and with pharma, biotech and healthcare.

Novartis plans inclisiran trial in the UK

Novartis plans inclisiran trial in the UK

In attendance was Health Secretary Matt Hancock, who formally opened the new Novartis HQ. ... Pictured left to right: Vas Narasimhan (chief executive officer, Novartis), Mari Scheiffele (general manager UK &Ireland, Novartis Oncology), Health Secretary

Latest news

  • Rival Novartis, Merck drugs square up on rare lung cancer at ASCO Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

    An inflection point for MET-inhibitor class. Novartis and Merck KGaA have both reported phase 2 results with drugs designed to treat a rare form of non-small cell lung cancer ... Novartis’ capmatinib and Merck’s tepotinib both target the

  • One hit, one miss as FDA panel votes on Daiichi’s cancer drugs One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

    Novartis’ Rydapt (midostaurin) was the first FLT3 inhibitor to reach the market in 2017, and is used alongside chemotherapy for newly-diagnoses FLT3-positive AML. ... The Japanese company has plenty of other candidates in its emerging oncology pipeline

  • Alcon spun off, leaner Novartis raises profit forecast Alcon spun off, leaner Novartis raises profit forecast

    Expects three new launches in 2019. Novartis has posted a 7% increase in sales in the first quarter, and has increased its profit forecasts for the year. ... etanercept). As with most big pharma companies, oncology is a key focus for Novartis, and the

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    said Mari Scheiffele (pictured below), General Manager of Novartis Oncology UK &Ireland. ... Worldwide, Gilead has opened up a lead on Novartis, which confirmed last year that it was struggling with limited manufacturing capacity to produce the synthetic

  • BMS and Celgene announce $74bn merger BMS and Celgene announce $74bn merger

    Once cleared, the deal will create a combined company with revenues in excess of $34bn, making it the sector’s fourth biggest firm behind Pfizer, Novartis and Roche. ... Their combination will unquestionably cause heated discussion in rival's boardrooms

More from news
Approximately 4 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    David was until recently the head of Baxalta's oncology division, whose formation he led, guiding it through a series of acquisitions and partnering deals. ... Doing so was the latest move in a 25-year pharma career that has also encompassed stints at

  • Choosing destiny Choosing destiny

    For instance, if Novo Nordisk designs a secular grail model by combining IBM's Watson with its own therapies, it will be different from, for example, Novartis' secular grail model combining ... immuno-oncology and companion diagnostics.

  • Deal Watch June 2016 Deal Watch June 2016

    Protein engineering - towards enhanced biologics. Also active in immuno-oncology, Novartis signed a broad collaboration and licence agreement with Xencor worth a potential $2.56bn covering two bispecific, tumour targeting antibodies, ... Tiered low

  • Deal Watch May 2016 Deal Watch May 2016

    Not under pressure as are GSK and Pfizer, Novartis announced the separation of its pharmaceuticals division into two business units: Novartis Oncology and Novartis Pharmaceuticals. ... The pharmaceuticals company will include Novartis' other interests in

  • Pharma deals in June 2015 Pharma deals in June 2015

    This was the case following the $20bn asset swap deal announced in April 2014 in which Novartis and GSK swapped vaccine and oncology assets. ... Licence, collaboration. 364. Spinifex Pharmaceuticals/ Novartis. Lead candidate EMA401 - oral treatment for

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Coughlin is a trained oncologist and immunologist with seasoned experience in developing oncology therapeutics. ... This includes serving as executive director of oncology clinical development at Novartis, and asset team leader in early clinical

  • New hires at Bristol-Myers Squibb, Acceleron and FerGene New hires at Bristol-Myers Squibb, Acceleron and FerGene

    Backstrom initially joined Celgene in 2008 as vice president, clinical R&D, with a focus on haematology and oncology. ... He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    She succeeds Bruno Strigini who retires. Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland. ... Prior to her time with Pfizer, Barrett held roles with Cephalon andchief executive

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry. ... Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients. ... Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with

More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics